SI4028017T1 - 1,4-dihidrobenzo(d)pirazolo(3,4-f)(1,3)diazepin derivati in sorodne spojine kot modulatorji lrrk2, nuak1 in/ali tyk2 kinaze za zdravljenje npr. avtoimunske bolezni - Google Patents
1,4-dihidrobenzo(d)pirazolo(3,4-f)(1,3)diazepin derivati in sorodne spojine kot modulatorji lrrk2, nuak1 in/ali tyk2 kinaze za zdravljenje npr. avtoimunske bolezniInfo
- Publication number
- SI4028017T1 SI4028017T1 SI202030353T SI202030353T SI4028017T1 SI 4028017 T1 SI4028017 T1 SI 4028017T1 SI 202030353 T SI202030353 T SI 202030353T SI 202030353 T SI202030353 T SI 202030353T SI 4028017 T1 SI4028017 T1 SI 4028017T1
- Authority
- SI
- Slovenia
- Prior art keywords
- nuak1
- lrrk2
- dihydrobenzo
- pyrazolo
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- ORQJPWRNWPJVTJ-UHFFFAOYSA-N N1N=CC2=C1C1=C(N=CN2)C=CC=C1 Chemical class N1N=CC2=C1C1=C(N=CN2)C=CC=C1 ORQJPWRNWPJVTJ-UHFFFAOYSA-N 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899908P | 2019-09-13 | 2019-09-13 | |
| PCT/IB2020/000730 WO2021048620A1 (en) | 2019-09-13 | 2020-09-11 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease |
| EP20788868.6A EP4028017B1 (en) | 2019-09-13 | 2020-09-11 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4028017T1 true SI4028017T1 (sl) | 2024-04-30 |
Family
ID=72801756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202030353T SI4028017T1 (sl) | 2019-09-13 | 2020-09-11 | 1,4-dihidrobenzo(d)pirazolo(3,4-f)(1,3)diazepin derivati in sorodne spojine kot modulatorji lrrk2, nuak1 in/ali tyk2 kinaze za zdravljenje npr. avtoimunske bolezni |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220380374A1 (sl) |
| EP (2) | EP4327884A3 (sl) |
| JP (1) | JP2022548246A (sl) |
| KR (1) | KR20220062038A (sl) |
| CN (1) | CN114793435A (sl) |
| AU (1) | AU2020344216A1 (sl) |
| CA (1) | CA3154123A1 (sl) |
| DK (1) | DK4028017T3 (sl) |
| ES (1) | ES2969088T3 (sl) |
| FI (1) | FI4028017T3 (sl) |
| IL (1) | IL291335A (sl) |
| PL (1) | PL4028017T3 (sl) |
| PT (1) | PT4028017T (sl) |
| RS (1) | RS65045B1 (sl) |
| SI (1) | SI4028017T1 (sl) |
| WO (1) | WO2021048620A1 (sl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140927A1 (es) * | 2011-04-21 | 2014-08-24 | Origenis Gmbh | Compuestos heterociclicos como inhibidores de cinasas |
-
2020
- 2020-09-11 AU AU2020344216A patent/AU2020344216A1/en active Pending
- 2020-09-11 WO PCT/IB2020/000730 patent/WO2021048620A1/en active Application Filing
- 2020-09-11 EP EP23205855.2A patent/EP4327884A3/en active Pending
- 2020-09-11 DK DK20788868.6T patent/DK4028017T3/da active
- 2020-09-11 CA CA3154123A patent/CA3154123A1/en active Pending
- 2020-09-11 ES ES20788868T patent/ES2969088T3/es active Active
- 2020-09-11 JP JP2022516097A patent/JP2022548246A/ja active Pending
- 2020-09-11 PT PT207888686T patent/PT4028017T/pt unknown
- 2020-09-11 CN CN202080078998.0A patent/CN114793435A/zh active Pending
- 2020-09-11 KR KR1020227011532A patent/KR20220062038A/ko unknown
- 2020-09-11 EP EP20788868.6A patent/EP4028017B1/en active Active
- 2020-09-11 SI SI202030353T patent/SI4028017T1/sl unknown
- 2020-09-11 FI FIEP20788868.6T patent/FI4028017T3/fi active
- 2020-09-11 US US17/642,142 patent/US20220380374A1/en active Pending
- 2020-09-11 RS RS20240045A patent/RS65045B1/sr unknown
- 2020-09-11 PL PL20788868.6T patent/PL4028017T3/pl unknown
-
2022
- 2022-03-13 IL IL291335A patent/IL291335A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3154123A1 (en) | 2021-03-18 |
| AU2020344216A1 (en) | 2022-03-31 |
| US20220380374A1 (en) | 2022-12-01 |
| ES2969088T3 (es) | 2024-05-16 |
| KR20220062038A (ko) | 2022-05-13 |
| WO2021048620A1 (en) | 2021-03-18 |
| CN114793435A (zh) | 2022-07-26 |
| EP4028017A1 (en) | 2022-07-20 |
| FI4028017T3 (fi) | 2024-01-11 |
| EP4327884A2 (en) | 2024-02-28 |
| PT4028017T (pt) | 2024-01-16 |
| EP4327884A3 (en) | 2024-05-01 |
| EP4028017B1 (en) | 2023-12-06 |
| IL291335A (en) | 2022-05-01 |
| JP2022548246A (ja) | 2022-11-17 |
| RS65045B1 (sr) | 2024-02-29 |
| PL4028017T3 (pl) | 2024-03-18 |
| DK4028017T3 (da) | 2024-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500775A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| SA519401544B1 (ar) | [1، 5-a] مركبات بيرازولو بيريدين بها استبدال كمثبطات كيناز معاد ترتيبه أثناء نقل العدوى | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| TWI799513B (zh) | 用於治療細胞介素相關之病症之jak1路徑抑制劑 | |
| AU2017261291A1 (en) | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| SG10201810660QA (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
| IL279144A (en) | Tetrahydro-1H-pyrazino[2,1-azisoindolylquinoline compounds for the treatment of immune system disease | |
| PH12018502168A1 (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
| WO2020041169A3 (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| DK3737684T3 (da) | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-on-derivater og relaterede forbindelser som c5a-receptormodulatorer til behandling af vaskulitis og inflammatoriske sygdomme | |
| IL286870A (en) | Hexahydro-h1-pyrazino[a-2,1]pyrazine compounds for the treatment of autoimmune disease | |
| MX2019013198A (es) | Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9). | |
| MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
| IL291338A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| IL291335A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| EP3937947A4 (en) | TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| EP3846803A4 (en) | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | |
| GB201918444D0 (en) | The integration platform of the community system | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose |